The molecular features of chronic lung allograft dysfunction in lung transplant airway mucosa.


Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703

Informations de publication

Date de publication:
12 2022
Historique:
received: 11 04 2022
revised: 22 07 2022
accepted: 17 08 2022
pubmed: 27 9 2022
medline: 30 11 2022
entrez: 26 9 2022
Statut: ppublish

Résumé

Many lung transplants fail due to chronic lung allograft dysfunction (CLAD). We recently showed that transbronchial biopsies (TBBs) from CLAD patients manifest severe parenchymal injury and dedifferentiation, distinct from time-dependent changes. The present study explored time-selective and CLAD-selective transcripts in mucosal biopsies from the third bronchial bifurcation (3BMBs), compared to those in TBBs. We used genome-wide microarray measurements in 324 3BMBs to identify CLAD-selective changes as well as time-dependent changes and develop a CLAD classifier. CLAD-selective transcripts were identified with linear models for microarray data (limma) and were used to build an ensemble of 12 classifiers to predict CLAD. Hazard models and random forests were then used to predict the risk of graft loss using the CLAD classifier, transcript sets associated with rejection, injury, and time. T cell-mediated rejection and donor-specific antibody were increased in CLAD 3BMBs but most had no rejection. Like TBBs, 3BMBs showed a time-dependent increase in transcripts expressed in inflammatory cells that was not associated with CLAD or survival. Also like TBBs, the CLAD-selective transcripts in 3BMBs reflected severe parenchymal injury and dedifferentiation, not inflammation or rejection. While 3BMBs and TBBs did not overlap in their top 20 CLAD-selective transcripts, many CLAD-selective transcripts were significantly increased in both for example LOXL1, an enzyme controlling matrix remodeling. In Cox models for one-year survival, the 3BMB CLAD-selective transcripts and CLAD classifier predicted graft loss and correlated with CLAD stage. Many 3BMB CLAD-selective transcripts were also increased by injury in kidney transplants and correlated with decreased kidney survival, including LOXL1. Mucosal and transbronchial biopsies from CLAD patients reveal a diffuse molecular injury and dedifferentiation state that impacts prognosis and correlates with the physiologic disturbances. CLAD state in lung transplants shares features with failing kidney transplants, indicating elements shared by the injury responses of distressed organs.

Sections du résumé

BACKGROUND
Many lung transplants fail due to chronic lung allograft dysfunction (CLAD). We recently showed that transbronchial biopsies (TBBs) from CLAD patients manifest severe parenchymal injury and dedifferentiation, distinct from time-dependent changes. The present study explored time-selective and CLAD-selective transcripts in mucosal biopsies from the third bronchial bifurcation (3BMBs), compared to those in TBBs.
METHODS
We used genome-wide microarray measurements in 324 3BMBs to identify CLAD-selective changes as well as time-dependent changes and develop a CLAD classifier. CLAD-selective transcripts were identified with linear models for microarray data (limma) and were used to build an ensemble of 12 classifiers to predict CLAD. Hazard models and random forests were then used to predict the risk of graft loss using the CLAD classifier, transcript sets associated with rejection, injury, and time.
RESULTS
T cell-mediated rejection and donor-specific antibody were increased in CLAD 3BMBs but most had no rejection. Like TBBs, 3BMBs showed a time-dependent increase in transcripts expressed in inflammatory cells that was not associated with CLAD or survival. Also like TBBs, the CLAD-selective transcripts in 3BMBs reflected severe parenchymal injury and dedifferentiation, not inflammation or rejection. While 3BMBs and TBBs did not overlap in their top 20 CLAD-selective transcripts, many CLAD-selective transcripts were significantly increased in both for example LOXL1, an enzyme controlling matrix remodeling. In Cox models for one-year survival, the 3BMB CLAD-selective transcripts and CLAD classifier predicted graft loss and correlated with CLAD stage. Many 3BMB CLAD-selective transcripts were also increased by injury in kidney transplants and correlated with decreased kidney survival, including LOXL1.
CONCLUSIONS
Mucosal and transbronchial biopsies from CLAD patients reveal a diffuse molecular injury and dedifferentiation state that impacts prognosis and correlates with the physiologic disturbances. CLAD state in lung transplants shares features with failing kidney transplants, indicating elements shared by the injury responses of distressed organs.

Identifiants

pubmed: 36163162
pii: S1053-2498(22)02078-2
doi: 10.1016/j.healun.2022.08.014
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1689-1699

Informations de copyright

Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Auteurs

Kieran Halloran (K)

University of Alberta, Edmonton, Alberta, Canada.

Martina Mackova (M)

University of Alberta, Edmonton, Alberta, Canada.

Michael D Parkes (MD)

University of Alberta, Edmonton, Alberta, Canada.

Alim Hirji (A)

University of Alberta, Edmonton, Alberta, Canada.

Justin Weinkauf (J)

University of Alberta, Edmonton, Alberta, Canada.

Irina L Timofte (IL)

University of Maryland, Baltimore, Maryland.

Greg I Snell (GI)

Alfred Hospital Lung Transplant Service, Melbourne, Victoria, Australia.

Glen P Westall (GP)

Alfred Hospital Lung Transplant Service, Melbourne, Victoria, Australia.

Robert Lischke (R)

University Hospital Motol, Prague, Czech Republic.

Andrea Zajacova (A)

University Hospital Motol, Prague, Czech Republic.

Jan Havlin (J)

University Hospital Motol, Prague, Czech Republic.

Ramsey Hachem (R)

Washington University in St Louis, St. Louis, Missouri.

Daniel Kreisel (D)

Washington University in St Louis, St. Louis, Missouri.

Deborah Levine (D)

University of Texas at San Antonio, San Antonio, Texas.

Bartosz Kubisa (B)

Pomeranian Medical University, Szczecin, Poland.

Maria Piotrowska (M)

Pomeranian Medical University, Szczecin, Poland.

Stephen Juvet (S)

Toronto Lung Transplant Program, University Health Network, Toronto, Ontario, Canada.

Shaf Keshavjee (S)

Toronto Lung Transplant Program, University Health Network, Toronto, Ontario, Canada.

Peter Jaksch (P)

Medical University of Vienna, Vienna, Austria.

Walter Klepetko (W)

Medical University of Vienna, Vienna, Austria.

Philip F Halloran (PF)

University of Alberta, Edmonton, Alberta, Canada. Electronic address: phallora@ualberta.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH